How can Abzena rapidly advance your next-generation biologic or bioconjugate while reducing risk & ensuring scalability?

From discovery and early development through to commercialization, there are many stages and complex challenges to overcome to meet your goals. Abzena is uniquely placed, at any stage, to partner with you across our integrated programs.

Abzena offers a focused approach:

• Fully integrated end-to-end biologics development partner with services that span early R&D through commercial capabilities
• High-quality and trusted data that drives development to increase the likelihood of clinical and commercial success
• Streamlined regulatory support tailored to your program to ensure successful IND or BLA filing

We are a leading end-to-end complex biologic and bioconjugates CDMO + CRO with 6 integrated locations expanding to support end-to-end programs. Our integrated programs leverage over 20 years of experience in de-risking complex biologics, bioconjugates, including ADCs and AOCs, development, and manufacturing. We aim to be the integrated partner that you trust across all development stages, staying true to our values of Scientific Innovation, Quality, and Integrity.

At Abzena, we understand that the science of what we can do together is complex. Moving medicine forward can be risky and takes time. We cannot do this alone. We are always looking to help our customers accelerate toward a successful outcome. A future that moves new medicines forward through our combined scientific innovation that delivers life-changing treatments to the clinic and patients in need. That is why we have partnerships and collaborations with biopharma market leaders across our early development services and programs.